Literature DB >> 18580395

Coverage with evidence development: ethical issues and policy implications.

Franklin G Miller1, Steven D Pearson.   

Abstract

Coverage with evidence development (CED) is an evolving method of providing provisional access to novel medical interventions while generating the evidence needed to determine whether unconditional coverage is warranted. In this article we review the policy rationale for CED and present a normative analysis that addresses ethical concerns and policy implications.

Entities:  

Mesh：

Year:  2008        PMID： 18580395     DOI： 10.1097/MLR.0b013e3181789453

Source DB:  PubMed          Journal:  Med Care        ISSN： 0025-7079            Impact factor:   2.983


  10 in total

Review 1.  Relative efficacy of drugs: an emerging issue between regulatory agencies and third-party payers.

Authors:  Hans-Georg Eichler; Brigitte Bloechl-Daum; Eric Abadie; David Barnett; Franz König; Steven Pearson
Journal:  Nat Rev Drug Discov       Date:  2010-02-26       Impact factor: 84.694

2.  Certificate of need regulations and the diffusion of intensity-modulated radiotherapy.

Authors:  Bruce L Jacobs; Yun Zhang; Ted A Skolarus; John T Wei; James E Montie; Florian R Schroeck; Brent K Hollenbeck
Journal:  Urology       Date:  2012-09-19       Impact factor: 2.649

3.  A method for addressing research gaps in HTA, developed whilst evaluating robotic-assisted surgery: a proposal.

Authors:  Luciana Ballini; Silvia Minozzi; Antonella Negro; Giampiero Pirini; Roberto Grilli
Journal:  Health Res Policy Syst       Date:  2010-09-20

4.  Growth of high-cost intensity-modulated radiotherapy for prostate cancer raises concerns about overuse.

Authors:  Bruce L Jacobs; Yun Zhang; Ted A Skolarus; Brent K Hollenbeck
Journal:  Health Aff (Millwood)       Date:  2012-04       Impact factor: 6.301

Review 5.  Funding the unfundable: mechanisms for managing uncertainty in decisions on the introduction of new and innovative technologies into healthcare systems.

Authors:  Tania Stafinski; Christopher J McCabe; Devidas Menon
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

6.  Personalized medicine and genomics: challenges and opportunities in assessing effectiveness, cost-effectiveness, and future research priorities.

Authors:  Rena Conti; David L Veenstra; Katrina Armstrong; Lawrence J Lesko; Scott D Grosse
Journal:  Med Decis Making       Date:  2010-01-04       Impact factor: 2.583

7.  Policy-induced selection bias in pharmacoepidemiology: The example of coverage for Alzheimer's medications in British Columbia.

Authors:  Anat Fisher; Greg Carney; Ken Bassett; K Malcolm Maclure; Colin R Dormuth
Journal:  Pharmacoepidemiol Drug Saf       Date:  2019-07-03       Impact factor: 2.890

8.  Politics and its intersection with coverage with evidence development: a qualitative analysis from expert interviews.

Authors:  Danielle Bishop; Joel Lexchin
Journal:  BMC Health Serv Res       Date:  2013-03-09       Impact factor: 2.655

9.  Routine real-time cost-effectiveness monitoring of a web-based depression intervention: a risk-sharing proposal.

Authors:  Klemen Naveršnik; Aleš Mrhar
Journal:  J Med Internet Res       Date:  2014-02-27       Impact factor: 5.428

10.  A real world example of coverage with evidence development in Australia - ipilimumab for the treatment of metastatic melanoma.

Authors:  Hansoo Kim; Samantha Comey; Karl Hausler; Greg Cook
Journal:  J Pharm Policy Pract       Date:  2018-02-13
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.